Pancreatic Cancer Study Program – National Institute of ... | 合法藥品大搜索

ONIVYDETM.OneofthemostexcitingachievementofNICRinthepastyearsisthesuccessofaglobal,randomizedphaseIIINAPOLI- ...

This translational study program has integrated basic scientists and clinical investigators of NICR and NCKUH to dissect pancreatic cancer (PDAC) from various aspects including case-controlled epidemiological study, basic and translational research focused on drug resistance, cancer stem cells, metabolism, microenvironment, and their interactions, and clinical trials. We have built 3D tissuemimetic model, zebrafish dissemination model, and orthotopic xenograft and transgenic mouse models for preclinical research, and also collected clinical samples from our collaborators in NCKUH and clinical trials to support this program.

ONIVYDETM

One of the most exciting achievement of NICR in the past years is the success of a global, randomized phase III NAPOLI-1 trial to show the superiority of liposomal irinotecan+5-FU/LV (nal-IRI, MM-398, PEP02) compared to 5-FU/LV alone in prolong the survival of pat...

Onivyde (irinotecan liposome injection) for the Treatment of ... | 合法藥品大搜索

Metastatic Pancreatic Cancer Treatment Option | 合法藥品大搜索

ONIVYDE (irinotecan liposome injection) is proven to help people with metastatic pancreatic cancer, who previously received gemcitabine chemotherapy, live ... Read More

Liposomal Irinotecan | 合法藥品大搜索

由 JE Frampton 著作 · 2020 · 被引用 4 次 — Key words were liposomal irinotecan, Onivyde, pancreatic cancer. Records were limited to those in ... Read More

FDA grants fast track designation to Onivyde for advanced ... | 合法藥品大搜索

2020年6月17日 — “Since the initial approval of Onivyde in metastatic pancreatic cancer, we have continued to dedicate our research efforts to better understand ... Read More

Pancreatic Cancer Study Program – National Institute of ... | 合法藥品大搜索

ONIVYDETM. One of the most exciting achievement of NICR in the past years is the success of a global, randomized phase III NAPOLI- ... Read More

NAPOLI | 合法藥品大搜索

由 A Wang-Gillam 著作 · 2019 · 被引用 65 次 — Longer overall survival in metastatic pancreatic cancer post–first line ... Liposomal irinotecan (nal-IRI; Onivyde®; Ipsen Biopharmaceuticals, Inc. Read More

Onivyde (Irinotecan Liposome Injection) a New Treatment ... | 合法藥品大搜索

由 LA Raedler 著作 · 被引用 1 次 — The FDA approval of irinotecan liposome injection has added a new treatment option for patients with pancreatic cancer. The drug is only approved for use in ... Read More

Ipsen receives FDA Fast Track designation for liposomal ... | 合法藥品大搜索

2020年6月17日 — “Since the initial approval of ONIVYDE® in metastatic pancreatic cancer, we have continued to dedicate our research efforts to better ... Read More

The safety and efficacy of Onivyde (irinotecan liposome ... | 合法藥品大搜索

由 FC Passero Jr 著作 · 2016 · 被引用 61 次 — Introduction: Patients with advanced and metastatic pancreatic cancer refractory to gemcitabine based therapy have a dismal prognosis and limited therapeutic ... Read More

Liposomal Irinotecan Regimen Pushes Toward Frontline ... | 合法藥品大搜索

2020年8月18日 — ... the NAPOLI-1 and NAPOLI-3 trials in metastatic pancreatic cancer, ... In October 2015, the FDA approved liposomal irinotecan (Onivyde) in ... Read More

相關資訊整理